# Vives Louvain Technology Fund

> Vives Louvain Technology Fund is a VC fund backing Health Care and Biotechnology. See 27 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Louvain-la-neuve, Belgium
- Total investments: 27
- Last investment: Mar 2023
- Lead investor: 4%
- Fund size: $37M
- Last fund: Sep 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/vives-louvain-technology-fund/about/
- X (Twitter): https://twitter.com/VIVES_Fund
- Website: http://www.vivesfund.com

Vives Louvain Technology Fund is a VC fund in Louvain-la-neuve focused on Health Care and Biotechnology. Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.6M–$7.3M |
| Series A | $491k–$46M |
| Series B | $4.7M–$125M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 26% |
| Biotechnology | 6 | 22% |
| Medical | 2 | 7% |
| Wellness | 2 | 7% |
| Nutrition | 2 | 7% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 22% |
| Series B | 6 | 22% |
| Seed | 3 | 11% |
| Funding Round | 3 | 11% |
| Series C | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 9 | 33% |
| France | 2 | 7% |
| United States | 2 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $18M | Series A | Mar 09, 2023 |  |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M | Series B | Nov 03, 2022 |  |
| BOTALYS | OUR MISSIONWe are Botanical Explorers seeking the next frontier of plant health benefits while preserving wild biotopes. We firmly believe that medicinal plants deserve a new standard of uncompromising quality, and we are committed to explore their health potential further while respecting the planet. Hence, our two core values: Explore &Respect.OUR VISIONIndoor Precision Farming offers a unique opportunity to sustainably grow potent medicinal plants. We have developed our own indoor farming approach under ultra-clean conditions. Our cultivation facilities are one of the largest vertical farms in Europe. There, by optimizing the growth environment, we ensure that our botanicals reach their full potential in terms of Health benefits, bringing full-spectrum product to the next level, and combining Wild Quality with Lab purity.OUR PRODUCTWith more than 3000 years of medicinal tradition and more than 5000 scientific publications about its health benefits, Korean red ginseng (Panax ginseng CA Meyer) is, without a doubt, the most precious and revered medicinal plant in the world. At BOTALYS, we are shaping its molecular profile, making our full-spectrum ginseng root powder comparable to a 20 years old wild Korean ginseng specimen.And ginseng is just the first botanical milestone of our journey… | $6.6M | Series B | Oct 04, 2022 |  |
| BOTALYS | OUR MISSIONWe are Botanical Explorers seeking the next frontier of plant health benefits while preserving wild biotopes. We firmly believe that medicinal plants deserve a new standard of uncompromising quality, and we are committed to explore their health potential further while respecting the planet. Hence, our two core values: Explore &Respect.OUR VISIONIndoor Precision Farming offers a unique opportunity to sustainably grow potent medicinal plants. We have developed our own indoor farming approach under ultra-clean conditions. Our cultivation facilities are one of the largest vertical farms in Europe. There, by optimizing the growth environment, we ensure that our botanicals reach their full potential in terms of Health benefits, bringing full-spectrum product to the next level, and combining Wild Quality with Lab purity.OUR PRODUCTWith more than 3000 years of medicinal tradition and more than 5000 scientific publications about its health benefits, Korean red ginseng (Panax ginseng CA Meyer) is, without a doubt, the most precious and revered medicinal plant in the world. At BOTALYS, we are shaping its molecular profile, making our full-spectrum ginseng root powder comparable to a 20 years old wild Korean ginseng specimen.And ginseng is just the first botanical milestone of our journey… | $987K | Convertible Note | Oct 04, 2022 |  |
| Spinovit | Spinovit, a UCLouvain spin-off, is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction and prevent risks. |  | Seed | Jan 01, 2022 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $7.3M | Seed | Dec 15, 2021 |  |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $22.2M | Series B | Oct 28, 2021 |  |
| Aphea.Bio | Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptakeof nutrients from the soil. | $21.6M | Series B | Apr 14, 2021 |  |
| Aphea.Bio | Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptakeof nutrients from the soil. | $4.7M | Series B | Apr 01, 2021 |  |
| Syndesi Therapeutics | Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. | $6.6M | Series A | Sep 28, 2020 |  |

10 of 27 investments shown.

## Co-investors
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 10 deals together
- [V-Bio Ventures](https://shizune.co/investors/profile/v-bio-ventures) — VC Fund, 5 deals together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 4 deals together
- [VIB](https://shizune.co/investors/profile/vib) — VC Fund, 4 deals together
- [Agri Investment Fund](https://shizune.co/investors/profile/agri-investment-fund) — VC Fund, 3 deals together
- [Airbus Ventures](https://shizune.co/investors/profile/airbus-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)

## FAQ

### What does Vives Louvain Technology Fund invest in?

Vives Louvain Technology Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Vives Louvain Technology Fund's check size?

Vives Louvain Technology Fund typically joins rounds of $1.6M–$7.3M at Seed, $491k–$46M at Series A and $4.7M–$125M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vives Louvain Technology Fund participates in.

### When did Vives Louvain Technology Fund last invest?

The most recent investment recorded for Vives Louvain Technology Fund closed in Mar 2023. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co